New positive inotropic substances--true inotropy or peripheral effects?

Area of Science:

• Cardiology
• Pharmacology
• Physiology

Background:

• Many substances augment myocardial contractility through increased intracellular calcium.
• Current clinical focus is on agents increasing myocyte cyclic AMP, despite calcium channel research.
• Inotropic agents exhibit chronotropic, lusitropic, and vasodilatory effects, with species and age variations.

Purpose of the Study:

• To investigate the effects of inotropic agents on myocardial contractility in various cardiac states.
• To explore the mechanisms of attenuated drug response in heart failure.
• To evaluate the in vivo efficacy and safety of these agents in normal and failing hearts.

Main Methods:

• Assessment of contractility in isolated animal and human myocardial preparations.
• Comparison of responses in healthy myocardium versus myocardium from heart failure patients.
• In vivo hemodynamic and metabolic assessments in patients with varying cardiac function.

Main Results:

• Inotropic agents increase contractility in healthy human myocardium but show attenuated effects in chronic and severe heart failure.
• Reduced receptor sensitivity or impaired cyclic AMP signaling may explain the blunted response in heart failure.
• In vivo, these drugs are harmful in normal cardiac function (lowering blood pressure, increasing heart rate) but beneficial in severe heart failure (improving hemodynamics).

Conclusions:

• The efficacy of inotropic agents, particularly those acting via cyclic AMP, is significantly diminished in heart failure.
• These agents have a narrow therapeutic window, posing risks in normal cardiac function but offering benefits in severe heart failure.
• Further research is needed to understand the underlying mechanisms of drug resistance in heart failure.